IMAGINT

HER Imaging and Molecular Interaction Mapping in Breast Cancer

Coordinatore	UNIVERSITY COLLEGE LONDON    more  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Ms. Nome: Greta Cognome: Borg-Carbott Email: send email Telefono: +44 20 3108 3033 Fax: +44 20 7813 2849
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	7˙411˙567 €
EC contributo	5˙683˙589 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2010-two-stage
Funding Scheme	CP-FP
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-05-01   -   2015-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY COLLEGE LONDON  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Ms. Nome: Greta Cognome: Borg-Carbott Email: send email Telefono: +44 20 3108 3033 Fax: +44 20 7813 2849	UK (LONDON)	coordinator	1˙678˙111.00
2	UNIVERSITAET ZUERICH  Organization address address: Raemistrasse 71 city: ZURICH postcode: 8006 contact info Titolo: Prof. Nome: Andreas Cognome: Plueckthun Email: send email Telefono: +41 44 6355570 Fax: +41 44 6355712	CH (ZURICH)	participant	1˙057˙073.00
3	KING'S COLLEGE LONDON  Organization address address: Strand city: LONDON postcode: WC2R 2LS contact info Titolo: Dr. Nome: Tony Cognome: Ng Email: send email Telefono: +44 0207 848 8056 Fax: +44 0207 848 6220	UK (LONDON)	participant	635˙749.00
4	UPPSALA UNIVERSITET  Organization address address: SANKT OLOFSGATAN 10 B city: UPPSALA postcode: 751 05 contact info Titolo: Dr. Nome: Anders Cognome: Alderborn Email: send email Telefono: 46184712577	SE (UPPSALA)	participant	545˙736.00
5	TOPOSNOMOS LTD  Organization address address: CALDERVALE ROAD THE PICASSO city: WAKEFIELD postcode: WF1 5PF contact info Titolo: Dr. Nome: Walter Cognome: Schubert Email: send email Telefono: +49 391 6117175 Fax: +49 3929228040	UK (WAKEFIELD)	participant	435˙454.75
6	Innovative Technologies in Biological Systems  Organization address city: Derio postcode: 48160 contact info Titolo: Dr. Nome: Salado Cognome: Clarisa Email: send email Telefono: 34944005355 Fax: 34946579925	ES (Derio)	participant	417˙600.00
7	MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.  Organization address address: Hofgartenstrasse 8 city: MUENCHEN postcode: 80539 contact info Titolo: Mr. Nome: Manfred Cognome: Messerschmidt Email: send email Telefono: +49 551 2011221 Fax: +49 551 2011331	DE (MUENCHEN)	participant	394˙300.00
8	FIRALIS S.A.S.  Organization address address: Rue du Fort city: Huningue postcode: 68330 contact info Titolo: Prof. Nome: Hüseyin Cognome: Firat Email: send email Telefono: +33 981 654 553 Fax: +33 981 708 433	FR (Huningue)	participant	326˙194.00
9	NOVAMEN SAS  Organization address city: LYON postcode: 69002 contact info Titolo: Dr. Nome: Marie-Laure Cognome: Muiras Email: send email Telefono: +33 4 78 92 40 00 Fax: +33 4 78 92 40 01	FR (LYON)	participant	193˙372.00
10	ACIES Consulting Group SAS  Organization address city: LYON postcode: 69002 contact info Titolo: Dr. Nome: Marie-Laure Cognome: Muiras Email: send email Telefono: +33 4 78 92 40 00 Fax: +33 4 78 92 40 01	FR (LYON)	participant	0.00
11	MEDIPOLIS GMP OY  Organization address address: Kiviharjuntie city: OULU postcode: 90220 contact info Titolo: Dr. Nome: Ashesh Cognome: Kumar Email: send email Telefono: 358400000000 Fax: +358 207 545 879	FI (OULU)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The aim is to develop tools for imaging and characterising protein/protein and protein/RNA interactions in cancer using Designed Ankyrin Repeat Proteins (DARPins). DARPins are small, ultrahighly stable, antibody-like proteins that bind specific targets with high affinity in monovalent form and are readily engineered for site-specific chemical modification. The exemplar protein family will be EGFR, with focus on HER2-mediated processes in cancer. 1. EGFR-reactive DARPins will be used to characterise HER2 homo- and hetero-dimers using 4 novel technologies: Single Molecule Fluorescence, Proximity Ligation, super-resolution microscopy and FRET/FLIM. The collected data will be analysed with information on clinical outcome to determine which HER2 interactions are associated with resistance to HER2 targeted treatments. 2. Protein/RNA complexes will be isolated and characterised. These complexes may be new biomarkers for breast cancer and their characterisation is aimed at elucidating mechanisms of transcriptional regulation in response to anti-HER2 treatment. 3. Protein networks associated with EGFR signalling by imaging clusters of at 50-100 different proteins in a single cell or tissue section. This will be achieved with a robot, using large dye-conjugated tag libraries, and automatically bleaching a dye after imaging and re-labelling with another. 4. Whole body imaging (Phase I/II) clinical trial will use radiolabelled anti-HER2 DARPins to improve specificity and sensitivity of quantitative PET/SPECT/CT. The trial aims to image HER2 positive metastatic cancer and provide circulating tumour cells (CTCs) and biopsies for more detailed analysis. 5. Multivariate data obtained by the new technologies will be analysed with a range of bioinformatic tools, including artificial neural network methods, to determine novel biomarkers that aim to classify breast cancer patients at an individualised level. The outcome is to increase the tool panel of clinicians.'